title: Normative comparison of patient-reported outcomes in patients with noninfectious uveitis.
abstract: OBJECTIVE
  To compare vision-related functioning and health-related quality of life of patients with noninfectious intermediate or posterior uveitis with those of the US general population and normal-vision reference groups.
  
  
  METHODS
  Secondary analysis of health-related quality of life measures administered at baseline to patients with noninfectious intermediate or posterior uveitis participating in the HURON trial, a 26-week, multicenter, masked, randomized, sham-controlled trial of a dexamethasone intravitreal implant (n=224) was performed. Patient-reported outcome measures included the National Eye Institute Visual Function Questionnaire-25, the 36-Item Short-Form Health Survey, the Short Form-6 Dimensions, and the EuroQol-5D. The National Eye Institute Visual Function Questionnaire-25 scores from the HURON uveitis population were compared with published National Eye Institute Visual Function Questionnaire-25 scores from a normal-vision reference group (n=122). The 36-Item Short-Form Health Survey, Short Form-6 Dimensions, and EuroQol-5D scores were compared with the US general population using data from the National Health Measurement Study (n=3844) and the Medical Expenditure Panel Survey (n=955).
  
  
  RESULTS
  Compared with a normal-vision population, the HURON uveitis population had clinically significant impairments across all National Eye Institute Visual Function Questionnaire-25 subscales and the composite score, with all subscale score differences exceeding 10 points (P< .001). The HURON uveitis population had significantly lower 36-Item Short-Form Health Survey mental component summary and Short Form-6 Dimensions scores compared with a US general population sample (P< .001). No significant differences were found for the 36-Item Short-Form Health Survey physical component summary and EuroQol-5D scores between the uveitis and US general population samples.
  
  
  CONCLUSIONS
  Compared with the US general population and normal-vision reference groups, noninfectious intermediate or posterior uveitis results in meaningful reductions in mental health outcomes, health-related quality of life, and vision-related functioning.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier:NCT00333814.
authors: Allergan Inc, Irvine, California 92612, USA. naik_rupali@allergan.com
authors: Rupali K
authors: RK
authors: Naik
authors: Anne M
authors: AM
authors: Rentz
authors: C Stephen
authors: CS
authors: Foster
authors: Susan
authors: S
authors: Lightman
authors: Rubens
authors: R
authors: Belfort
authors: Careen
authors: C
authors: Lowder
authors: Scott M
authors: SM
authors: Whitcup
authors: Jonathan W
authors: JW
authors: Kowalski
authors: Dennis A
authors: DA
authors: Revicki
mesh_terms: D000328:Adult; D003907:Dexamethasone / Q000008:administration & dosage*; D004311:Double-Blind Method; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D017060:Patient Satisfaction; D011788:Quality of Life; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D015867:Uveitis, Intermediate / Q000188:drug therapy* / Q000503:physiopathology; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone